Switch To Branded denied as experimental or investigational by Humana?

Humana's specific coverage criteria for switch to branded are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Called a Switch to the Branded Drug Experimental — and How to Appeal

Labeling a request for a branded medication as "experimental" or "investigational" is an unusual but documented denial tactic, typically applied when the prescriber's stated clinical rationale for the branded formulation over its generic equivalent references a use, route, or indication that Humana has not yet classified as established. This can also occur when a branded drug has a newer indication or formulation not yet reflected in the plan's evidence review.

## Why This Denial Is Appealable

For a drug that holds FDA approval for the indication being treated, an "experimental" or "investigational" classification is very difficult for the plan to sustain on appeal — particularly before an independent reviewer. The FDA approval itself is the baseline standard for established medical use. If your prescriber is requesting the branded version for an FDA-approved indication, the experimental label mischaracterizes the request.

Your appeal rights: - Internal appeal (ACA §2719 / ERISA §503): File within 180 days. The plan must specify which evidence standard it used and why the branded drug fails it. - External review: An independent review organization applies objective, evidence-based standards — not Humana's internal formulary classification. The window is generally up to four months from final internal denial. - Expedited review (72 hours): Available if delay poses serious health risk.

## What to Gather

• FDA approval documentation: Print the FDA label for the branded drug showing approval for your specific indication. This is the cornerstone of your appeal.
• Published clinical guidelines: A reference (not a quote of numbers) to the relevant professional society guideline (e.g., the applicable specialty society's current treatment guideline) confirming the use as standard of care.
• Prescriber medical-necessity letter: Should state the FDA-approved indication being treated, cite guideline organization support, and explicitly dispute the experimental classification.
• Denial letter analysis: Note which evidence review or policy Humana cited. Request the full clinical policy document if not attached.

## Criteria-Mapping Structure

| Humana's Experimental Claim | Your Rebuttal Evidence | |---|---| | Drug/use not established | FDA approval letter/label for this indication | | Not supported by clinical evidence | Reference to applicable specialty guideline organization endorsement | | [Any other cited criterion] | Prescriber letter directly addressing each point |

Your appeal letter should open by stating that the branded drug carries FDA approval for the indication your prescriber is treating, attach the label, and then systematically address each basis Humana cited for the experimental classification. External reviewers overturn experimental denials at high rates when FDA approval is clearly documented.